

Trends in Risks Associated With New Drug Development Drugs

Clinical Pharmacology and Therapeutics

87, 272-277

DOI: 10.1038/clpt.2009.295

Citation Report

#	ARTICLE	IF	CITATIONS
1	Perestroika in Pharma: Evolution or Revolution in Drug Development?. Mount Sinai Journal of Medicine, 2010, 77, 327-332.	1.9	9
2	Deconstructing the Drug Development Process: The New Face of Innovation. Clinical Pharmacology and Therapeutics, 2010, 87, 356-361.	2.3	311
3	The Economics of Drug Development: A Grim Reality and a Role for Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 2010, 87, 247-251.	2.3	33
4	Probabilistic Risk Analysis: Improving Early Drug Development Decision Making. Clinical Pharmacology and Therapeutics, 2010, 88, 871-875.	2.3	9
5	Envisioning the future of early anticancer drug development. Nature Reviews Cancer, 2010, 10, 514-523.	12.8	262
6	New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options. SSRN Electronic Journal, 0, , .	0.4	13
7	Endothelial vascular smooth muscle cell coculture assay for high throughput screening assays to identify antiangiogenic and other therapeutic molecules. International Journal of High Throughput Screening, 2010, 2010, 171.	0.5	55
8	The Success Rate of New Drug Development in Clinical Trials: Crohn's Disease. Journal of Pharmacy and Pharmaceutical Sciences, 2010, 13, 191.	0.9	22
9	Bar the Windows but Open the Door to Randomization. Journal of Clinical Oncology, 2010, 28, 3104-3106.	0.8	18
10	Safe and effective medicines for all: is personalized medicine the answer?. Expert Review of Clinical Pharmacology, 2010, 3, 627-637.	1.3	1
11	Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification. Biomarkers in Medicine, 2011, 5, 497-514.	0.6	22
12	Drug development risk in HIV-1 clinical trials: the effect of drug class. Journal of Pharmaceutical Health Services Research, 2011, 2, 211-216.	0.3	13
13	Clinical Trial Risk in Non-Hodgkin's Lymphoma: Endpoint and Target Selection. Journal of Pharmacy and Pharmaceutical Sciences, 2011, 14, 227.	0.9	18
14	Study design and patient characteristics and outcome in acute mania clinical trials. Bipolar Disorders, 2011, 13, 125-132.	1.1	11
15	Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000-2009. Clinical Pharmacology and Therapeutics, 2011, 89, 183-188.	2.3	287
16	Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Drug Discovery Today, 2011, 16, 73-80.	3.2	37
17	Planning for demand failure: A dynamic lot size model for clinical trial supply chains. European Journal of Operational Research, 2011, 211, 496-506.	3.5	23
18	Microfluidic Cell Culture and Its Application in High-Throughput Drug Screening: Cardiotoxicity Assay for hERG Channels. Journal of Biomolecular Screening, 2011, 16, 101-111.	2.6	63

#	ARTICLE	IF	CITATIONS
19	Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs. JAMA - Journal of the American Medical Association, 2011, 306, 2608.	3.8	63
20	Death of the "Blockbuster"™ and "Pivotal"™ Clinical Trial: Rethinking the Drug Development Process. Journal of Pharmacy Practice and Research, 2011, 41, 94-96.	0.5	0
21	Knowledge management for efficient quantitative analyses during regulatory reviews. Expert Review of Clinical Pharmacology, 2011, 4, 697-703.	1.3	6
22	Design-for-Six-Sigma for Development of a Bioprocess Quality-by-Design Framework. PDA Journal of Pharmaceutical Science and Technology, 2011, 65, 254-286.	0.3	10
23	Risk of Failure of a Clinical Drug Trial in Patients with Moderate to Severe Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 2066-2070.	1.0	16
24	Influence of Decisions Related to Business and Regulatory Considerations on Therapeutic Development for Kidney Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1195-1199.	2.2	1
25	A Comparison of the Quality of Data, Assessed Using Query Rates, From Clinical Trials Conducted Across Developed Versus Emerging Global Regions. Drug Information Journal, 2012, 46, 455-463.	0.5	7
26	Analyzing global trends of biomarker use in drug interventional clinical studies. Drug Discoveries and Therapeutics, 2012, , .	0.6	4
27	Business models and opportunities for cancer vaccine developers. Human Vaccines and Immunotherapeutics, 2012, 8, 1431-1438.	1.4	4
28	Revolution Stalled. Science Translational Medicine, 2012, 4, 155cm11.	5.8	207
29	A Paradigm Shift in Drug Development for Treatment of Rare Multidrug-Resistant Gram-Negative Pathogens. Clinical Infectious Diseases, 2012, 55, 562-567.	2.9	17
30	Maximizing the value of diagnostics in Alzheimer's disease drug development. Nature Reviews Drug Discovery, 2012, 11, 183-184.	21.5	4
31	Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins. , 2012, , 15-595.		0
32	Size of clinical trials and Introductory prices of prophylactic vaccine series. Human Vaccines and Immunotherapeutics, 2012, 8, 1066-1070.	1.4	7
33	Risk, resources and structures: Experimental evidence of a new cost of risk component " The structural risk component and implications for enterprise risk management. Risk Management, 2012, 14, 152-175.	1.2	4
34	Translational Research and the Evolving Landscape for Biomedical Innovation. Journal of Investigative Medicine, 2012, 60, 995-998.	0.7	16
35	Pharmacodynamic end points in early-phase oncology trials. Clinical Investigation, 2012, 2, 679-687.	0.0	0
36	Portfolio and Project Planning and Management in the Drug Discovery, Evaluation, Development, and Regulatory Review Process. , 2012, , 487-506.		2

#	ARTICLE	IF	CITATIONS
37	Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection. , 2012, , 175-196.		0
38	The Invention of an Investment Incentive for Pharmaceutical Innovation. Journal of World Intellectual Property, 2012, 15, 305-364.	0.2	2
39	Introduction to the special volume: Gene therapy for neurologic disease. Neuroscience Letters, 2012, 527, 61.	1.0	1
40	Building bridges to the future of medicine: recommendations for boosting development of novel and companion diagnostics. Pharmacogenomics, 2012, 13, 1651-1659.	0.6	3
41	Design of Clinical Development Programs. , 2012, , 571-593.		0
42	ADME of Biologicsâ€”What Have We Learned from Small Molecules?. AAPS Journal, 2012, 14, 410-419.	2.2	52
44	Immunogenicity to Biologics: Mechanisms, Prediction and Reduction. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 331-344.	1.0	99
45	Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Research and Treatment, 2012, 136, 179-185.	1.1	28
47	Open innovation: the new face of pharmaceutical research and development. Expert Review of Clinical Pharmacology, 2012, 5, 481-483.	1.3	19
48	Overview of cancer vaccines. Human Vaccines and Immunotherapeutics, 2012, 8, 1335-1353.	1.4	19
49	Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 2012, 11, 191-200.	21.5	1,520
50	Analysis of the success rates of new drug development in Japan and the lag behind the US. Health Policy, 2012, 104, 241-246.	1.4	20
51	Animal models and conserved processes. Theoretical Biology and Medical Modelling, 2012, 9, 40.	2.1	35
52	Drug development and clinical trialsâ€”the path to an approved cancer drug. Nature Reviews Clinical Oncology, 2012, 9, 215-222.	12.5	107
53	Extracting Knowledge from Failed Development Programmes. Pharmaceutical Medicine, 2012, 26, 91-96.	1.0	6
54	The High Cost of Cancer Drugs and What We Can Do About It. Mayo Clinic Proceedings, 2012, 87, 935-943.	1.4	189
55	A decade of cell therapy clinical trials (2000â€”2010). Regenerative Medicine, 2012, 7, 455-462.	0.8	60
56	Unraveling the autoimmune translational research process layer by layer. Nature Medicine, 2012, 18, 35-41.	15.2	50

#	ARTICLE	IF	CITATIONS
58	Pharmacodynamic and Clinical Endpoints for Functional Colonic Disorders: Statistical Considerations. <i>Digestive Diseases and Sciences</i> , 2012, 58, 509-18.	1.1	21
60	R&D Costs and Returns to New Drug Development: A Review of the Evidence. , 0, , 21-46.		22
61	Rational Approaches to Improving Selectivity in Drug Design. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1424-1444.	2.9	248
62	Integrated Teaching of Structure-Based Drug Design and Biopharmaceutics: A Computer-Based Approach. <i>Journal of Chemical Education</i> , 2012, 89, 45-51.	1.1	20
63	Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. <i>Science and Engineering Ethics</i> , 2012, 18, 247-261.	1.7	130
64	Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. <i>Drug Discovery Today</i> , 2012, 17, 419-424.	3.2	589
65	Neonatal seizures: controversies and challenges in translating new therapies from the lab to the isolette. <i>European Journal of Neuroscience</i> , 2012, 35, 1857-1865.	1.2	37
66	Analysis of 10 years drug lifecycle management (LCM) activities in the Japanese market. <i>Drug Discovery Today</i> , 2013, 18, 1109-1116.	3.2	8
67	Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 161-166.	1.1	7
68	Prodrugs as self-assembled hydrogels: a new paradigm for biomaterials. <i>Current Opinion in Biotechnology</i> , 2013, 24, 1174-1182.	3.3	67
69	Clinical Approval Success Rates for Investigational Cancer Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 329-335.	2.3	166
70	Questions regarding the predictive value of one evolved complex adaptive system for a second: Exemplified by the SOD1 mouse. <i>Progress in Biophysics and Molecular Biology</i> , 2013, 113, 231-253.	1.4	33
71	Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs. <i>Pharmacological Reviews</i> , 2013, 65, 1053-1090.	7.1	248
73	Innovating by Developing New Uses of Already-Approved Drugs: Trends in the Marketing Approval of Supplemental Indications. <i>Clinical Therapeutics</i> , 2013, 35, 808-818.	1.1	29
74	Fundamentals of Pharmaceutical Nanoscience. , 2013, , .		16
75	Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study. <i>Drug Safety</i> , 2013, 36, 1105-1115.	1.4	27
76	Analysis of new drugs whose clinical development and regulatory approval were hampered during their introduction in Japan. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 309-313.	0.7	3
77	Liquid refreshment. <i>Nature Biotechnology</i> , 2013, 31, 115-115.	9.4	0

#	ARTICLE	IF	CITATIONS
78	Systems Analysis of BCL2 Protein Family Interactions Establishes a Model to Predict Responses to Chemotherapy. <i>Cancer Research</i> , 2013, 73, 519-528.	0.4	94
79	Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 91-102.	1.0	51
80	Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. <i>Journal of Chromatography A</i> , 2013, 1284, 17-27.	1.8	121
81	Approval probabilities and regulatory review patterns for anticancer drugs in the European Union. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 112-121.	2.0	34
82	A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 269-275.	4.6	111
83	Therapeutic nanoparticles in clinics and under clinical evaluation. <i>Nanomedicine</i> , 2013, 8, 449-467.	1.7	206
84	Primate Models of Spinal Repair. <i>Neuromethods</i> , 2013, , 207-223.	0.2	0
85	Impact of biomarker usage on oncology drug development. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 62-67.	0.7	21
86	Challenges and opportunities of drug repositioning. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 267-272.	4.0	296
87	Translational medicine: mitigating risks for investigators. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 327-328.	21.5	5
88	Drug-Drug Interaction Studies: Regulatory Guidance and An Industry Perspective. <i>AAPS Journal</i> , 2013, 15, 629-645.	2.2	193
89	The structure and business of biopharmaceutical companies including the management of risks and resources. , 2013, , 225-253.		1
90	Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics. , 2013, , 161-203.		37
92	Impact of biomarkers on clinical trial risk. <i>Pharmacogenomics</i> , 2013, 14, 1645-1658.	0.6	6
93	Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. <i>Globalization and Health</i> , 2013, 9, 58.	2.4	34
94	Opening up drug development to everyone. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 311-315.	0.9	3
96	Injury and death in clinical trials and compensation: Rule 122 DAB. <i>Perspectives in Clinical Research</i> , 2013, 4, 199.	0.5	3
97	Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation. <i>Clinical Cancer Research</i> , 2013, 19, 2929-2940.	3.2	34

#	ARTICLE	IF	CITATIONS
98	Factors Related to Regulatory Approval of Late-Stage Development Compounds: Analysis of Japanese Pharmaceutical Company Activities, 1995–2007. Therapeutic Innovation and Regulatory Science, 2013, 47, 261-267.	0.8	1
99	Protein Replacement Therapies for Rare Diseases: A Breeze for Regulatory Approval?. Science Translational Medicine, 2013, 5, 178fs10.	5.8	27
100	Evaluating and utilizing probability of study success in clinical development. Clinical Trials, 2013, 10, 407-413.	0.7	44
101	Improving Oncology Clinical Programs by Use of Innovative Designs and Comparing Them via Simulations. Therapeutic Innovation and Regulatory Science, 2013, 47, 602-612.	0.8	16
102	Joint probability of statistical success of multiple phase III trials. Pharmaceutical Statistics, 2013, 12, 358-365.	0.7	5
103	Making the biotech IPO work. Nature Biotechnology, 2013, 31, 969-970.	9.4	5
104	Not a Clinical simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions. British Journal of Clinical Pharmacology, 2013, 76, 964-972.	1.1	13
105	Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium. Drug Development Research, 2013, 74, 112-126.	1.4	11
106	Developability assessment as an early de-risking tool for biopharmaceutical development. Pharmaceutical Bioprocessing, 2013, 1, 29-50.	0.8	51
107	Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration. Oncologist, 2013, 18, 104-111.	1.9	31
108	ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools. Bioanalysis, 2013, 5, 2003-2014.	0.6	15
109	Quantifying the Strength of Evidence: A Few Additional Comments on Interim Analyses. , 2013, , 147-150.		0
110	Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti-Interferon- γ Receptor Antibody. Clinical Pharmacology and Therapeutics, 2013, 93, 483-492.	2.3	56
111	New Zealand's Drug Development Industry. International Journal of Environmental Research and Public Health, 2013, 10, 4339-4351.	1.2	6
112	Prospects for Rapid Advances in the Development of New Medicines for Special Medical Needs. Clinical Pharmacology and Therapeutics, 2013, 95, 98-109.	2.3	17
113	Translating Drugs From Animals to Humans: Do We Need to Prove Efficacy?. Translational Vision Science and Technology, 2013, 2, 1.	1.1	15
114	Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical Companies. PLoS ONE, 2013, 8, e71966.	1.1	23
115	Clinical development. , 2013, , 239-258.		0

#	ARTICLE	IF	CITATIONS
116	Clinical Trial Risk in Type-2 Diabetes: Importance of Patient History. Journal of Pharmacy and Pharmaceutical Sciences, 2014, 17, 393.	0.9	2
117	Failure Modes in Anticancer Drug Discovery and Development. , 2014, , 567-581.		0
118	Quantification of human mAbs in mouse tissues using generic affinity enrichment procedures and LC-MS detection. Bioanalysis, 2014, 6, 1795-1811.	0.6	27
119	Extracting drug mechanism and pharmacodynamic information from clinical electroencephalographic data using generalised semi-linear canonical correlation analysis. Physiological Measurement, 2014, 35, 2459-2474.	1.2	2
120	A Celebration of Failure. Circulation, 2014, 129, 953-955.	1.6	12
121	Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012. JAMA - Journal of the American Medical Association, 2014, 311, 378.	3.8	164
122	Pharmacologic Management of Duchenne Muscular Dystrophy: Target Identification and Preclinical Trials. ILAR Journal, 2014, 55, 119-149.	1.8	44
123	Phases of Clinical Development. Ocular Surface, 2014, 12, 307-311.	2.2	0
124	Pharmaceutical new product development: why do clinical trials fail?. R and D Management, 2014, 44, 189-202.	3.0	15
125	Identifying novel interventional strategies for psychiatric disorders: integrating genomics, <i>enviromics</i> [™] and gene-environment interactions in valid preclinical models. British Journal of Pharmacology, 2014, 171, 4719-4728.	2.7	38
126	The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times. Therapeutic Innovation and Regulatory Science, 2014, 48, 482-487.	0.8	14
127	Tracking the Pharmaceutical Pipeline: Clinical Trials and Global Disease Burden. Clinical and Translational Science, 2014, 7, 297-299.	1.5	6
129	A novel protocol for assessing exercise performance and dystropathophysiology in the <i>mdx</i> mouse. Muscle and Nerve, 2014, 50, 541-548.	1.0	15
130	Chapter 11. Human Microdosing/Phase 0 Studies to Accelerate Drug Development. RSC Drug Discovery Series, 2014, , 241-266.	0.2	0
131	Model Driven Process Design and Development for a Continuous Process. Organic Process Research and Development, 2014, 18, 1391-1399.	1.3	6
132	A community of practice approach to bioanalysis delivery: the role of the Preclinical Bioanalysis and Toxicokinetics department at AstraZeneca. Bioanalysis, 2014, 6, 1329-1337.	0.6	4
133	Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 163-169.	0.5	44
134	A Quantitative Process for Enhancing End of Phase 2 Decisions. Statistics in Biopharmaceutical Research, 2014, 6, 67-77.	0.6	17

#	ARTICLE	IF	CITATIONS
135	Pharmaceutical R&D Performance by Firm Size. American Journal of Therapeutics, 2014, 21, 26-34.	0.5	26
136	Learnings from other types of risk management. , 2014, , 371-378.		0
137	The Significance of Nanoparticles in Medicine and Their Potential Application in Asthma. , 2014, , 247-275.		3
138	Translating Drugs From Animals to Humans. JAMA Ophthalmology, 2014, 132, 667.	1.4	0
139	Building an Integrated Early Clinical Development Platform to Improve the Path to Proof of Concept. Therapeutic Innovation and Regulatory Science, 2014, 48, 546-551.	0.8	0
140	Synthesis and evaluation of cyclohexane carboxylic acid head group containing isoxazole and thiazole analogs as DGAT1 inhibitors. European Journal of Medicinal Chemistry, 2014, 79, 203-215.	2.6	7
141	Knowing when to leap: Transitioning between exploitative and explorative <sc>R&D</sc>. Strategic Management Journal, 2014, 35, 126-145.	4.7	159
142	Application of Translational Science to Clinical Development. , 2014, , 1-21.		1
143	Efficient clinical trials in Japan: Bridging studies versus participation in global clinical trials. Journal of Clinical Pharmacology, 2014, 54, 438-445.	1.0	13
144	Medical Imaging in Clinical Trials. , 2014, , .		19
145	In vitroâ€“in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discovery Today, 2014, 19, 275-281.	3.2	22
146	Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials. Clinical Pharmacology and Therapeutics, 2014, 95, 617-626.	2.3	107
147	Reply to Gelman, Gaudart, Pericchi: More reasons to revise standards for statistical evidence. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1936-7.	3.3	3
148	Systems biology-embedded target validation: improving efficacy in drug discovery. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 1-11.	6.6	19
149	Target small firms for antibiotic innovation. Science, 2014, 344, 967-969.	6.0	15
150	â€“Project Launchâ€™: From research finding to therapeutic product. European Journal of Pharmaceutical Sciences, 2014, 51, 123-136.	1.9	3
152	Photopharmacology: Beyond Proof of Principle. Journal of the American Chemical Society, 2014, 136, 2178-2191.	6.6	875
153	Clinical development success rates for investigational drugs. Nature Biotechnology, 2014, 32, 40-51.	9.4	1,885

#	ARTICLE	IF	CITATIONS
154	Toward a Jurisprudence of Drug Regulation. <i>Journal of Law, Medicine and Ethics</i> , 2014, 42, 244-262.	0.4	5
155	Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs. <i>Neuron</i> , 2014, 84, 554-563.	3.8	58
156	Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?. <i>Lancet Neurology</i> , The, 2014, 13, 1127-1138.	4.9	240
157	The Biotechnology Innovation Machine: A Source of Intelligent Biopharmaceuticals for the Pharma Industry “Mapping Biotechnology”’s Success. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 528-532.	2.3	20
158	Integrated Partnerships and the Transformation of Pharmaceutical Research and Development. <i>Clinical Therapeutics</i> , 2014, 36, 1346-1348.	1.1	4
159	Taking the Pulse of Strategic Outsourcing Relationships. <i>Clinical Therapeutics</i> , 2014, 36, 1349-1355.	1.1	11
160	Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise. <i>BJU International</i> , 2014, 113, E82-E89.	1.3	9
161	Microphysiological modeling of the reproductive tract: A fertile endeavor. <i>Experimental Biology and Medicine</i> , 2014, 239, 1192-1202.	1.1	25
162	The Scientific Quest for Lasting Youth: Prospects for Curing Aging. <i>Rejuvenation Research</i> , 2014, 17, 458-467.	0.9	39
163	The Impracticality of Biomedical Rejuvenation Therapies: Translational and Pharmacological Barriers. <i>Rejuvenation Research</i> , 2014, 17, 390-396.	0.9	9
164	Microfluidic 3D models of cancer. <i>Advanced Drug Delivery Reviews</i> , 2014, 79-80, 68-78.	6.6	156
165	More in vivo experimentation is needed in cardiovascular physiology. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H121-H123.	1.5	5
166	WIPO Re:Search: Catalyzing Collaborations to Accelerate Product Development for Diseases of Poverty. <i>Chemical Reviews</i> , 2014, 114, 11272-11279.	23.0	5
167	Mechanistic Understanding of Brain Drug Disposition to Optimize the Selection of Potential Neurotherapeutics in Drug Discovery. <i>Pharmaceutical Research</i> , 2014, 31, 2203-2219.	1.7	55
168	Making drug development visible “and viable. <i>Drug Discovery Today</i> , 2014, 19, 1-3.	3.2	12
170	Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology. <i>Pharmaceutical Medicine</i> , 2014, 28, 53-65.	1.0	6
171	Improving clinical trial efficiency by biomarker-guided patient selection. <i>Trials</i> , 2014, 15, 103.	0.7	16
172	Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. <i>Nature Medicine</i> , 2014, 20, 591-593.	15.2	95

#	ARTICLE	IF	CITATIONS
173	Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks. <i>Nature Medicine</i> , 2014, 20, 590-591.	15.2	169
174	Can pharmaco-electroencephalography help improve survival of central nervous system drugs in early clinical development?. <i>Drug Discovery Today</i> , 2014, 19, 282-288.	3.2	19
175	Financing drug discovery for orphan diseases. <i>Drug Discovery Today</i> , 2014, 19, 533-538.	3.2	43
176	Regenerative Bladder Augmentation Using Autologous Tissue—When Will We Get There?. <i>Journal of Urology</i> , 2014, 191, 1204-1205.	0.2	21
177	How multi-organ microdevices can help foster drug development. <i>Advanced Drug Delivery Reviews</i> , 2014, 69-70, 158-169.	6.6	134
178	Neurological drug development: A guide for a start-up biotech. <i>Neurobiology of Disease</i> , 2014, 61, 1-5.	2.1	1
179	Vaccine R&D: Past performance is no guide to the future. <i>Vaccine</i> , 2014, 32, 2139-2142.	1.7	10
180	Molecular mechanisms and physiology of disease. , 2014, , .		1
181	Functional magnetic resonance imaging of intrinsic brain networks for translational drug discovery. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 397-403.	4.0	57
182	The use of phase 2 interim analysis to expedite drug development decisions. <i>Contemporary Clinical Trials</i> , 2014, 38, 235-244.	0.8	2
183	Pay-for-Delay Agreements in the Pharmaceutical Sector: Towards a Coherent EU Approach?. <i>European Journal of Risk Regulation</i> , 2014, 5, 79-86.	0.8	1
184	Novel methodology for pharmaceutical expenditure forecast. <i>Journal of Market Access & Health Policy</i> , 2014, 2, 24082.	0.8	4
186	Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 12-27.	1.3	66
188	Regulating Antibiotics in an Era of Resistance: The Historical Basis and Continued Need for Adequate and Well-Controlled Investigations. <i>Annals of Internal Medicine</i> , 2015, 163, 386.	2.0	6
189	Medication Nonadherence, “Professional Subjects,” and Apparent Placebo Responders. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 566-573.	0.7	51
190	Advancing knowledge requires both clinical and basic research. <i>Focus on Alternative and Complementary Therapies</i> , 2015, 20, 32-33.	0.1	1
191	A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 506-513.	2.3	29
192	Surrogate endpoints in clinical trials of chronic kidney disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 492-497.	1.0	6

#	ARTICLE	IF	CITATIONS
193	What have we learned from exceptional tumour responses?. Current Opinion in Oncology, 2015, 27, 267-275.	1.1	8
194	Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive Licensing. Reviews on Recent Clinical Trials, 2015, 10, 28-43.	0.4	8
195	Reverse Innovation and Reverse Technology Transfer: From Made in China to Discovered in China in the Pharmaceutical Sector. Management International, 2015, 19, 49-69.	0.1	10
196	R&D internationalisation patterns in the global pharmaceutical industry: evidence from a network analytic perspective. Technology Analysis and Strategic Management, 2015, 27, 532-549.	2.0	22
197	The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals. Expert Opinion on Therapeutic Patents, 2015, 25, 739-742.	2.4	25
198	Effect of a pharmacologically induced decrease in core temperature in rats resuscitated from cardiac arrest. Resuscitation, 2015, 92, 26-31.	1.3	9
200	Combination of onâ€line CE assay with MS detection for the study of drug metabolism by cytochromes P450. Electrophoresis, 2015, 36, 1365-1373.	1.3	11
201	Animal Paradigms to Assess Cognition with Translation to Humans. Handbook of Experimental Pharmacology, 2015, 228, 27-57.	0.9	21
202	Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors. Therapeutic Innovation and Regulatory Science, 2015, 49, 352-358.	0.8	7
203	Expectations for methodology and translation of animal research: a survey of health care workers. BMC Medical Ethics, 2015, 16, 29.	1.0	2
204	The Life Sciences Translational Challenge: The European Perspective. Therapeutic Innovation and Regulatory Science, 2015, 49, 415-424.	0.8	2
205	Early Decision-Making in Drug Development: The Potential Role of Pharmaco-EEG and Pharmaco-Sleep. Neuropsychobiology, 2015, 72, 188-194.	0.9	7
206	Predictive Value Tools as an Aid in Chemopreventive Agent Development. Journal of the National Cancer Institute, 2015, 107, djv259.	3.0	3
207	The therapeutic monoclonal antibody market. MAbs, 2015, 7, 9-14.	2.6	1,049
208	The Right to Try. Ocular Surface, 2015, 13, 88-91.	2.2	13
209	Emerging proteomic technologies for elucidating context-dependent cellular signaling events: A big challenge of tiny proportions. Proteomics, 2015, 15, 1486-1502.	1.3	9
210	Digital Microfluidics for Automated Hanging Drop Cell Spheroid Culture. Journal of the Association for Laboratory Automation, 2015, 20, 283-295.	2.8	72
211	The Decline Of Venture Capital Investment In Early-Stage Life Sciences Poses A Challenge To Continued Innovation. Health Affairs, 2015, 34, 271-276.	2.5	36

#	ARTICLE	IF	CITATIONS
212	The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA. <i>Pharmacoeconomics</i> , 2015, 33, 643-653.	1.7	30
213	Why Is the Pharmaceutical and Biotechnology Industry Struggling?. , 2015, , 3-15.		4
216	Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity. <i>Clinical Therapeutics</i> , 2015, 37, 1643-1651.e3.	1.1	14
217	What does the current biotech stock market value?. <i>Nature Biotechnology</i> , 2015, 33, 813-814.	9.4	2
218	Bayesian Design of Proof-of-Concept Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 155-162.	0.8	42
219	Safety Pharmacology Evaluation of Biopharmaceuticals. <i>Handbook of Experimental Pharmacology</i> , 2015, 229, 385-404.	0.9	3
220	Do We Need a Science of Science?. , 2015, , 3-53.		0
221	The support of human genetic evidence for approved drug indications. <i>Nature Genetics</i> , 2015, 47, 856-860.	9.4	1,112
222	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	1.2	168
223	Translating slow-binding inhibition kinetics into cellular and in vivo effects. <i>Nature Chemical Biology</i> , 2015, 11, 416-423.	3.9	127
224	A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. <i>Science Translational Medicine</i> , 2015, 7, 284ra58.	5.8	76
225	Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets. <i>Chemical Society Reviews</i> , 2015, 44, 8773-8785.	18.7	174
226	Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma. <i>Biomarkers in Medicine</i> , 2015, 9, 13-23.	0.6	14
227	Accelerating Proof-of-Concept by Smart Early Clinical Trials. , 2015, , 243-247.		0
228	Cyclosporine A kinetics in brain cell cultures and its potential of crossing the blood-brain barrier. <i>Toxicology in Vitro</i> , 2015, 30, 166-175.	1.1	20
229	Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation. <i>Translational Psychiatry</i> , 2015, 5, e587-e587.	2.4	21
230	The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation. <i>Pharmacoeconomics</i> , 2015, 33, 749-763.	1.7	2
231	A critical appraisal of clinical trials conducted and subsequent drug approvals in India and South Africa. <i>BMJ Open</i> , 2015, 5, e007304.	0.8	10

#	ARTICLE	IF	CITATIONS
232	Quantitative structure-activity relationship: promising advances in drug discovery platforms. Expert Opinion on Drug Discovery, 2015, 10, 1283-1300.	2.5	96
233	Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety. Handbook of Experimental Pharmacology, 2015, 232, 235-260.	0.9	46
234	Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. Journal of Nuclear Medicine, 2015, 56, 1793-1799.	2.8	10
235	The Quest to Develop New Medicines to Treat Alzheimer's Disease: Present Trends and Future Prospects. Clinical Therapeutics, 2015, 37, 1618-1621.	1.1	3
236	Industry Perspective on Alopecia Areata. Journal of Investigative Dermatology Symposium Proceedings, 2015, 17, 67-69.	0.8	3
237	Biophysical Characterization and Its Role in the Biopharmaceutical Industry. , 2015, , 23-47.		1
238	Peering into the pharmaceutical "pipeline": Investigational drugs, clinical trials, and industry priorities. Social Science and Medicine, 2015, 131, 322-330.	1.8	51
239	Do Human Leukocyte Antigen-Typed Cellular Therapeutics Based on Induced Pluripotent Stem Cells Make Commercial Sense?. Stem Cells and Development, 2015, 24, 1-10.	1.1	43
240	Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nature Reviews Clinical Oncology, 2015, 12, 197-212.	12.5	162
241	Discovering and Developing Molecules with Optimal Drug-Like Properties. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , .	0.2	8
242	The role of concentration-effect relationships in the assessment of QTc interval prolongation. British Journal of Clinical Pharmacology, 2015, 79, 117-131.	1.1	19
243	Stemming the Tide of Age-Related Macular Degeneration: New Therapies for Old Retinas. , 2016, 57, ORSFb1.		7
244	Stakeholder Views on Participant Selection for First-in-Human Trials in Cancer Nanomedicine. Current Oncology, 2016, 23, 530-537.	0.9	4
245	Microfluidic-Based Multi-Organ Platforms for Drug Discovery. Micromachines, 2016, 7, 162.	1.4	32
246	Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets. Biomedicines, 2016, 4, 27.	1.4	23
247	Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project. Trials, 2016, 17, 373.	0.7	22
248	Replication Validity of Initial Association Studies: A Comparison between Psychiatry, Neurology and Four Somatic Diseases. PLoS ONE, 2016, 11, e0158064.	1.1	22
249	Expectations for the Methodology and Translation of Animal Research: A Survey of the General Public, Medical Students and Animal Researchers in North America. ATLA Alternatives To Laboratory Animals, 2016, 44, 361-381.	0.7	6

#	ARTICLE	IF	CITATIONS
250	Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry. <i>Electrophoresis</i> , 2016, 37, 959-972.	1.3	23
251	Stock Market Response to Strategic Technical Alliances between Drug and Biotechnology Firms. <i>Journal of Product Innovation Management</i> , 2016, 33, 549-569.	5.2	11
253	Systems Pharmacology and Pharmacodynamics. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , .	0.2	9
254	Shapeshifting photoswitchable azobenzene compounds and their biological applications. , 2016, , .		0
255	Using Systems Pharmacology to Advance Oncology Drug Development. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 421-463.	0.2	1
256	New Approaches to Drug Discovery. <i>Handbook of Experimental Pharmacology</i> , 2016, , .	0.9	5
257	What Determines How Much Your Patient Pays for Their Medication in the United States?. <i>American Journal of Ophthalmology</i> , 2016, 167, 48-51.	1.7	8
258	Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years: From Theory to Therapy. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 759-768.	0.8	37
259	The evolution of drug discovery: from phenotypes to targets, and back. <i>MedChemComm</i> , 2016, 7, 788-798.	3.5	31
260	Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1622-1635.	1.1	18
261	Systematic characterization of gastrointestinal clinical trials. <i>Digestive and Liver Disease</i> , 2016, 48, 480-488.	0.4	3
262	The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 939-956.	2.5	10
263	Pharmacometabolomics in Earlyâ€Phase Clinical Development. <i>Clinical and Translational Science</i> , 2016, 9, 128-138.	1.5	32
270	Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 993-1008.	4.0	156
272	A crowdsourcing workflow for extracting chemical-induced disease relations from free text. <i>Database: the Journal of Biological Databases and Curation</i> , 2016, 2016, baw051.	1.4	9
273	Changing R&D models in research-based pharmaceutical companies. <i>Journal of Translational Medicine</i> , 2016, 14, 105.	1.8	231
274	Technological area experience, experience diversity and innovation. <i>Technology Analysis and Strategic Management</i> , 2016, 28, 1041-1055.	2.0	3
275	Ethical considerations and challenges in first-in-human research. <i>Translational Research</i> , 2016, 177, 6-18.	2.2	5

#	ARTICLE	IF	CITATIONS
276	Use of big data in drug development for precision medicine. Expert Review of Precision Medicine and Drug Development, 2016, 1, 245-253.	0.4	28
277	Valuations using royalty data in the life sciences area—focused on anticancer and cardiovascular therapies. Journal of Open Innovation: Technology, Market, and Complexity, 2016, 2, 1-25.	2.6	18
278	Organ-on-a-Chip Systems: Microengineering to Biomimic Living Systems. Small, 2016, 12, 2253-2282.	5.2	245
279	Success rates for product development strategies in new drug development. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 198-202.	0.7	6
280	Mechanisms of Hybrid Governance: Administrative Committees in Non-Equity Alliances. Academy of Management Journal, 2016, 59, 510-533.	4.3	70
281	Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2016, 30, 59-64.	1.3	7
282	Targeting therapeutic liabilities engendered by <i>PIK3R1</i> mutations for cancer treatment. Pharmacogenomics, 2016, 17, 297-307.	0.6	36
283	Alternatives to antibiotics—a pipeline portfolio review. Lancet Infectious Diseases, The, 2016, 16, 239-251.	4.6	720
284	Integrative Genomics of Aging. , 2016, , 263-285.		6
286	Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization. Drug Discovery Today, 2016, 21, 299-305.	3.2	22
287	3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors. Molecular Cancer Therapeutics, 2016, 15, 753-763.	1.9	30
288	Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 2016, 47, 20-33.	1.3	2,229
289	On-line coupling of immobilized cytochrome P450 microreactor and capillary electrophoresis: A promising tool for drug development. Journal of Chromatography A, 2016, 1437, 234-240.	1.8	32
291	Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?. Current Hypertension Reports, 2016, 18, 25.	1.5	6
292	Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system. Journal of Controlled Release, 2016, 240, 251-266.	4.8	64
293	Toxicology Strategies for Drug Discovery: Present and Future. Chemical Research in Toxicology, 2016, 29, 473-504.	1.7	157
294	Reducing clinical trial risk in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 5, 81-88.	0.9	7
295	Risks of phase I research with healthy participants: A systematic review. Clinical Trials, 2016, 13, 149-160.	0.7	43

#	ARTICLE	IF	CITATIONS
296	Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 221-227.	0.8	15
297	A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. <i>Journal of Antibiotics</i> , 2016, 69, 73-88.	1.0	152
298	Factors That Affect the Acquisition of Reward Premiums for Promotion of Innovative Drug Discovery in Japan. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 56-65.	0.8	18
299	Regulatory aspects of small molecule drugs for heart regeneration. <i>Advanced Drug Delivery Reviews</i> , 2016, 96, 245-252.	6.6	7
300	Active Clinical Trials for Personalized Medicine. <i>Journal of the American Statistical Association</i> , 2016, 111, 875-887.	1.8	9
301	This isn't going to end well: Fictional representations of medical research in television and film. <i>Public Understanding of Science</i> , 2017, 26, 564-578.	1.6	12
302	Integrated, High-Throughput, Multiomics Platform Enables Data-Driven Construction of Cellular Responses and Reveals Global Drug Mechanisms of Action. <i>Journal of Proteome Research</i> , 2017, 16, 1364-1375.	1.8	34
303	Factors related to drug approvals: predictors of outcome?. <i>Drug Discovery Today</i> , 2017, 22, 937-946.	3.2	8
304	Improving access to high-cost cancer drugs in Latin America: Much to be done. <i>Cancer</i> , 2017, 123, 1313-1323.	2.0	31
305	Translating Molecules into Medicines. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2017, , .	0.2	2
306	Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 76, 4-21.	2.9	41
307	Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. <i>Biotechnology Progress</i> , 2017, 33, 854-866.	1.3	135
308	Design of Clinical Studies in Early Development. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2017, , 297-315.	0.2	0
309	Human genetics as a model for target validation: finding new therapies for diabetes. <i>Diabetologia</i> , 2017, 60, 960-970.	2.9	19
310	When Science is Not Enough: A Framework Towards More Customer-Focused Drug Development. <i>Advances in Therapy</i> , 2017, 34, 1572-1583.	1.3	0
311	Emerging Trends in Micro- and Nanoscale Technologies in Medicine: From Basic Discoveries to Translation. <i>ACS Nano</i> , 2017, 11, 5195-5214.	7.3	104
312	The Impact of R&D Cooperations and Mergers in Pharmaceuticals on Research Activities and Drugs Offered on the Market. <i>Southern Economic Journal</i> , 2017, 84, 202-228.	1.3	4
314	Chemistry matters!. <i>Ocular Surface</i> , 2017, 15, 264-267.	2.2	5

#	ARTICLE	IF	CITATIONS
315	Translatable Models of Brain and Cognitive Reserve. , 2017, , 79-104.		1
316	The Large Pharmaceutical Company Perspective. New England Journal of Medicine, 2017, 376, 52-60.	13.9	34
318	Critical Considerations in Anticancer Drug Development and Dosing Strategies: The Past, Present, and Future. Journal of Clinical Pharmacology, 2017, 57, S116-S128.	1.0	9
319	Quantitative LC/ESI-SRM/MS of antibody biopharmaceuticals: use of a homologous antibody as an internal standard and three-step method development. Analytical and Bioanalytical Chemistry, 2017, 409, 5523-5532.	1.9	7
320	Intra-Target Microdosing – A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans. Clinical and Translational Science, 2017, 10, 351-359.	1.5	6
321	The Burden of the “False Negatives” in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures. Clinical and Translational Science, 2017, 10, 470-479.	1.5	19
322	Drug discovery and development: Role of basic biological research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 651-657.	1.8	330
323	Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities. Clinical Therapeutics, 2017, 39, 1409-1425.e20.	1.1	23
324	Do investors value the FDA orphan drug designation?. Orphanet Journal of Rare Diseases, 2017, 12, 114.	1.2	18
325	Control of false positives in randomized phase III clinical trials. Journal of Biopharmaceutical Statistics, 2017, 27, 719-731.	0.4	2
326	Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treatment Reviews, 2017, 52, 12-21.	3.4	87
327	Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans – a practical guide. Expert Opinion on Drug Delivery, 2017, 14, 657-672.	2.4	30
328	A portable and reconfigurable multi-organ platform for drug development with onboard microfluidic flow control. Lab on A Chip, 2017, 17, 134-144.	3.1	88
329	Commercial Aspects of Vaccine Development. , 2017, , 411-421.		3
330	Lemons, or Squeezed for Resources? Information Symmetry and Asymmetric Resources in Biotechnology. Frontiers in Pharmacology, 2017, 8, 338.	1.6	3
331	Drug discovery. , 2017, , 183-279.		1
332	Background. , 2017, , 3-29.		0
333	Fabrication of In Vitro Cancer Microtissue Array on Fibroblast-Layered Nanofibrous Membrane by Inkjet Printing. International Journal of Molecular Sciences, 2017, 18, 2348.	1.8	18

#	ARTICLE	IF	CITATIONS
334	Global Challenges in Cardiovascular Drug Discovery and Clinical Trials. <i>Molecular Biology (Los Angeles)</i> , 2017, 10, 742-750.	0.0	3
335	New Models of Drug Discovery and Development for Neglected Disease Populations. <i>Journal of Pharmaceutical Sciences</i> , 2017, 96, 491-504.		0
336	Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays. <i>Oncotarget</i> , 2017, 8, 8854-8866.	0.8	78
337	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. <i>Journal of Pharmaceutical Sciences</i> , 2017, 96, 64-93.		0
338	Attack or Defend? The Role of Institutional Context on Patent Litigation Strategies. <i>Journal of Management</i> , 2018, 44, 1226-1249.	6.3	12
339	A Strategy for Optimizing the Combination of Active Components Based on Chinese Medicinal Formula Sheng-Mai-San for Myocardial Ischemia. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 1455-1471.	1.1	26
340	Human Stakeholders and the Use of Animals in Drug Development. <i>Business and Society Review</i> , 2018, 123, 3-58.	0.9	11
341	Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 261-274.	1.5	2
342	Probing characteristics of cancer cells cultured on engineered platforms simulating different microenvironments. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 1170-1179.	1.9	6
343	Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics. <i>Cancer Letters</i> , 2018, 421, 51-58.	3.2	31
344	Drugs and Devices Discovery Research: Preclinical Assays, Techniques, and Animal Model Studies for Ocular Hypotensives and Neuroprotectants. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 7-39.	0.6	32
345	Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980-2016). <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 847-855.	1.4	9
346	Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. <i>Circulation Research</i> , 2018, 122, 1021-1032.	2.0	111
347	The financial performance of the health care industry: a global, regional and industry specific empirical investigation. <i>European Journal of Health Economics</i> , 2018, 19, 585-594.	1.4	1
348	Alliances and the innovation performance of corporate and public research spin-off firms. <i>Small Business Economics</i> , 2018, 50, 763-781.	4.4	18
349	The signaling effects of incremental information: Evidence from stacked US Food and Drug Administration designations. <i>Quarterly Review of Economics and Finance</i> , 2018, 67, 219-226.	1.5	2
350	Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 19-33.	21.5	106
351	Organ-on-a-Chip Platforms: A Convergence of Advanced Materials, Cells, and Microscale Technologies. <i>Advanced Healthcare Materials</i> , 2018, 7, 1700506.	3.9	227

#	ARTICLE	IF	CITATIONS
352	Strategies for Drug Encapsulation and Controlled Delivery Based on Vapor-Phase Deposited Thin Films. <i>Advanced Engineering Materials</i> , 2018, 20, 1700639.	1.6	25
353	Organ-on-a-chip Systems. , 2018, , 55-78.		0
354	Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands. <i>Technological Forecasting and Social Change</i> , 2018, 128, 133-143.	6.2	23
355	The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classes. <i>Journal of Generic Medicines</i> , 2018, 14, 70-80.	0.0	6
356	Project Selection and Success: Insights from the Drug Discovery Process. <i>SSRN Electronic Journal</i> , 2018, , .	0.4	2
357	Factors Affecting Pricing in Patent Licensing Contracts in the Biopharmaceutical Industry. <i>Sustainability</i> , 2018, 10, 3143.	1.6	11
358	Difficulties with Applying a Strong Social Value Requirement to Clinical Research. <i>Hastings Center Report</i> , 2018, 48, 35-37.	0.7	0
359	Evaluating Determinant Priority of License Fee in Biotech Industry. <i>Journal of Open Innovation: Technology, Market, and Complexity</i> , 2018, 4, 30.	2.6	12
360	Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1315-1330.	1.5	11
361	Entangled Decisions: Knowledge Interdependencies and Terminations of Patented Inventions in the Pharmaceutical Industry. <i>SSRN Electronic Journal</i> , 2018, , .	0.4	0
362	Be open about drug failures to speed up research. <i>Nature</i> , 2018, 563, 317-319.	13.7	37
363	The impact of policy on the growth of precision medicine. <i>Health Policy and Technology</i> , 2018, 7, 347-357.	1.3	9
364	Managerial challenges of outbound open innovation: a study of a spinout initiative in AstraZeneca. <i>R and D Management</i> , 2019, 49, 652-667.	3.0	11
365	Virus-free and oncogene-free induced pluripotent stem cell reprogramming in cord blood and peripheral blood in patients with lung disease. <i>Regenerative Medicine</i> , 2018, 13, 889-915.	0.8	6
366	Net Present Value-Based Analyses of Products in Development by Pharmaceutical and Biotech Firms: NPV-Based Analyses of Biopharmaceutical Products. , 2018, , .		1
367	The challenge of new chemical entities attrition. <i>IBM Journal of Research and Development</i> , 2018, 62, 1:1-1:9.	3.2	0
368	Best Practices in Clinical Trial Simulations for Adaptive Study Designs. <i>ICSA Book Series in Statistics</i> , 2018, , 101-114.	0.0	1
369	Predicting a tumour's drug uptake. <i>Nature Biomedical Engineering</i> , 2018, 2, 717-718.	11.6	1

#	ARTICLE	IF	CITATIONS
370	Twenty-First Century Cures Act. Stroke, 2018, 49, 2555-2558.	1.0	1
371	Strategic decision-making in the pharmaceutical industry: A unified decision-making framework. Computers and Chemical Engineering, 2018, 119, 171-189.	2.0	12
372	The Challenges of Implementing Multiarmed Early Phase Oncology Clinical Trials. , 2018, , 47-55.		0
373	The inherent risks associated with newly traded biopharmaceutical firms. Drug Discovery Today, 2018, 23, 1680-1688.	3.2	1
374	The Current Status of Drug Discovery and Development as Originated in <scp>United States</scp> Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development. Clinical and Translational Science, 2018, 11, 597-606.	1.5	135
375	Entangled decisions: Knowledge interdependencies and terminations of patented inventions in the pharmaceutical industry. Strategic Management Journal, 2018, 39, 2439-2465.	4.7	19
376	Preformulation in Drug Research and Pharmaceutical Product Development. , 2018, , 1-55.		4
377	Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. International Journal of Molecular Sciences, 2018, 19, 1578.	1.8	703
378	R&D Project Valuation Considering Changes of Economic Environment: A Case of a Pharmaceutical R&D Project. Sustainability, 2018, 10, 993.	1.6	6
379	Select Advances in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners. Current Emergency and Hospital Medicine Reports, 2018, 6, 94-100.	0.6	0
380	Human Cortex Spheroid with a Functional Blood Brain Barrier for High-Throughput Neurotoxicity Screening and Disease Modeling. Scientific Reports, 2018, 8, 7413.	1.6	145
381	Recent milestone U.S. ophthalmic product approvals and clearances. Ocular Surface, 2018, 16, 487-491.	2.2	1
382	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. Psychotherapy and Psychosomatics, 2018, 87, 285-295.	4.0	39
383	Can Regenerative Medicine Help Close the Gap Between the Medicine Pipeline and Public Health Burden of Cardiovascular and Musculoskeletal Diseases?. Clinical Therapeutics, 2018, 40, 1066-1075.	1.1	3
384	Human Genetics of Obesity and Type 2 Diabetes Mellitus. Circulation Genomic and Precision Medicine, 2018, 11, e002090.	1.6	58
385	Predicting drug-disease associations and their therapeutic function based on the drug-disease association bipartite network. Methods, 2018, 145, 51-59.	1.9	104
386	Mechanisms and Drug Development in Atrial Fibrillation. Pharmacological Reviews, 2018, 70, 505-525.	7.1	67
387	Differentiation of innovation strategies based on pharmaceutical licensing agreements: Insight from Korean pharmaceutical firms. Technology Analysis and Strategic Management, 2019, 31, 169-185.	2.0	1

#	ARTICLE	IF	CITATIONS
388	Consortium-Based Open Innovation: Exploring a Unique and Optimal Model for Regional Biotechnology Industry. <i>Creative Economy</i> , 2019, , 141-171.	0.1	1
389	Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111602.	2.6	47
390	Altered Biodistribution and Tissue Retention of Nanoparticles Targeted with P-Glycoprotein Substrates. <i>Regenerative Engineering and Translational Medicine</i> , 2019, 5, 308-318.	1.6	1
391	Construction of pancreasâ€“muscleâ€“liver microphysiological system (MPS) for reproducing glucose metabolism. <i>Biotechnology and Bioengineering</i> , 2019, 116, 3433-3445.	1.7	22
392	In Silico Repositioning of Cannabigerol as a Novel Inhibitor of the Enoyl Acyl Carrier Protein (ACP) Reductase (InhA). <i>Molecules</i> , 2019, 24, 2567.	1.7	22
393	Japan oncology market overview: Current and future perspectives. <i>Journal of Generic Medicines</i> , 2019, 15, 104-114.	0.0	1
394	Randomized Phase III Oncology Trials: A Survey and Empirical Bayes Inference. <i>Journal of Statistical Theory and Practice</i> , 2019, 13, 1.	0.3	0
395	Developing an Improved Risk-Adjusted Net Present Value Technology Valuation Model for the Biopharmaceutical Industry. <i>Journal of Open Innovation: Technology, Market, and Complexity</i> , 2019, 5, 45.	2.6	7
396	Origins of Endobiogeny. , 2019, , 1-15.		3
397	Shortcuts to schistosomiasis drug discovery: The state-of-the-art. <i>Annual Reports in Medicinal Chemistry</i> , 2019, , 139-180.	0.5	3
398	Circular economy in action. , 2019, , 111-206.		1
399	EK-DRD: A Comprehensive Database for Drug Repositioning Inspired by Experimental Knowledge. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 3619-3624.	2.5	4
400	Perspectives on HCV Cure. <i>Topics in Medicinal Chemistry</i> , 2019, , 491-495.	0.4	0
401	Standardization of research methods employed in assessing the interaction between metallic-based nanoparticles and the blood-brain barrier: Present and future perspectives. <i>Journal of Controlled Release</i> , 2019, 296, 202-224.	4.8	12
402	Estimating Clinical Trial Success Rates and Related Parameters in Oncology. <i>SSRN Electronic Journal</i> , 0, , .	0.4	9
403	Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas. <i>BMJ Open</i> , 2019, 9, e027625.	0.8	8
404	Re: Rosenfeld etÂal.: Lessons from recent phase III trial failures: don't design phase III trials based on retrospective subgroup analyses from phase II trials (<i>Ophthalmology</i> . 2018;125:1488-1491). <i>Ophthalmology</i> , 2019, 126, e31-e32.	2.5	0
405	Dynamic scheduling of multi-product continuous biopharmaceutical facilities: A hyper-heuristic framework. <i>Computers and Chemical Engineering</i> , 2019, 125, 71-88.	2.0	13

#	ARTICLE	IF	CITATIONS
407	Recent In Silico Research in High-Throughput Drug Discovery and Molecular Biochemistry. Current Topics in Medicinal Chemistry, 2019, 19, 103-104.	1.0	2
408	A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. Scientific Reports, 2019, 9, 1407.	1.6	61
409	Delivery Systems as Vital Tools in Drug Repurposing. AAPS PharmSciTech, 2019, 20, 116.	1.5	23
410	Association of National Cancer Instituteâ€“Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. JAMA Network Open, 2019, 2, e1910593.	2.8	18
411	Lost in translation: the valley of death across preclinical and clinical divide â€“ identification of problems and overcoming obstacles. Translational Medicine Communications, 2019, 4, .	0.5	299
412	Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy. Therapeutic Innovation and Regulatory Science, 2019, , 216847901986012.	0.8	1
413	The Productivity of Drug Development: A Systematic Review. , 2019, , .		1
414	Medicines discovery for auditory disorders: Challenges for industry. Journal of the Acoustical Society of America, 2019, 146, 3652-3667.	0.5	12
415	Optimal sample size allocation and go/noâ€“go decision rules for phase II/III programs where several phase III trials are performed. Biometrical Journal, 2019, 61, 357-378.	0.6	3
416	Design principles for dynamic microphysiological systems. , 2019, , 1-29.		4
417	A rapid method for post-antibiotic bacterial susceptibility testing. PLoS ONE, 2019, 14, e0210534.	1.1	22
418	Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. MAbs, 2019, 11, 45-57.	2.6	96
419	A Review of Recent Patents Regarding Antithrombotic Drugs Derived From Natural Products. Studies in Natural Products Chemistry, 2019, , 1-47.	0.8	2
420	Advances in dynamic microphysiological organ-on-a-chip: Design principle and its biomedical application. Journal of Industrial and Engineering Chemistry, 2019, 71, 65-77.	2.9	28
421	Web-based drug repurposing tools: a survey. Briefings in Bioinformatics, 2019, 20, 299-316.	3.2	38
422	Improving the Progress of Research & Development (R&D) Projects by Selecting an Optimal Alliance Structure and Partner Type. British Journal of Management, 2019, 30, 791-809.	3.3	10
423	Estimation of clinical trial success rates and related parameters. Biostatistics, 2019, 20, 273-286.	0.9	879
424	Disadvantaged, outnumbered, and discouraged: womenâ€™s experiences as healthy volunteers in U.S. Phase I trials. Critical Public Health, 2020, 30, 141-152.	1.4	9

#	ARTICLE	IF	CITATIONS
425	A Framework for Assessing Disruptions in a Clinical Supply Chain Using Bayesian Belief Networks. <i>Journal of Pharmaceutical Innovation</i> , 2020, 15, 467-481.	1.1	8
426	Microfluidic Devices and 3D Printing for Synthesis and Screening of Drugs and Tissue Engineering. <i>Industrial & Engineering Chemistry Research</i> , 2020, 59, 3794-3810.	1.8	21
427	Organotypic and Microphysiological Models of Liver, Gut, and Kidney for Studies of Drug Metabolism, Pharmacokinetics, and Toxicity. <i>Chemical Research in Toxicology</i> , 2020, 33, 38-60.	1.7	30
428	Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 324-332.	2.3	26
429	Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data. <i>Annual Review of Pharmacology and Toxicology</i> , 2020, 60, 333-352.	4.2	39
430	Towards accurate high-throughput ligand affinity prediction by exploiting structural ensembles, docking metrics and ligand similarity. <i>Bioinformatics</i> , 2020, 36, 160-168.	1.8	19
431	Long-term perspective on venture capital investments in early stage life-science projects related to health care. <i>Economic Research-Ekonomska Istrazivanja</i> , 2020, 33, 2526-2540.	2.6	4
432	Mitigating the Challenges of Partner Knowledge Diversity While Enhancing Research & Development (R&D) Alliance Performance: The Role of Alliance Governance Mechanisms. <i>Journal of Product Innovation Management</i> , 2020, 37, 26-47.	5.2	25
433	Biophysical characterization and its role in the biopharmaceutical industry. , 2020, , 27-53.		0
434	Key indicators of phase transition for clinical trials through machine learning. <i>Drug Discovery Today</i> , 2020, 25, 414-421.	3.2	26
435	Ccrn4l as a pre-dose marker for prediction of cisplatin-induced hepatotoxicity susceptibility. <i>Free Radical Biology and Medicine</i> , 2020, 148, 128-139.	1.3	11
436	Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker. <i>Biometrika</i> , 2020, 107, 107-122.	1.3	25
437	Application and Impact of Human Dose Projection from Discovery to Early Drug Development. <i>AAPS PharmSciTech</i> , 2020, 21, 44.	1.5	1
438	FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 234.	1.2	10
439	Targeting Proteases for Treating COVID-19. <i>Journal of Proteome Research</i> , 2020, 19, 4316-4326.	1.8	68
440	Organotypic Models to Study Human Glioblastoma: Studying the Beast in Its Ecosystem. <i>IScience</i> , 2020, 23, 101633.	1.9	12
441	Effects of Hydrophobic Tail Length Variation on Surfactant-Mediated Protein Stabilization. <i>Molecular Pharmaceutics</i> , 2020, 17, 4302-4311.	2.3	10
442	in silico ADMET Screening of Compounds Present in <i>Cyanthillium cinereum</i> (L.) H. Rob.. <i>Asian Journal of Chemistry</i> , 2020, 32, 1421-1426.	0.1	1

#	ARTICLE	IF	CITATIONS
443	The economic consequences of US FDA new drug approvals: evidence from Taiwan pharmaceutical and biotech companies. <i>Innovation: Management, Policy and Practice</i> , 2020, , 1-21.	2.6	3
445	“Pulling the Plug:” Time Allocation between Drug Discovery and Development Projects. <i>Production and Operations Management</i> , 2020, 29, 2851-2876.	2.1	5
446	Trends of Business-to-Business Transactions to Develop Innovative Cancer Drugs. <i>Sustainability</i> , 2020, 12, 5535.	1.6	4
447	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	1.2	50
449	Optimal designs for phase II/III drug development programs including methods for discounting of phase II results. <i>BMC Medical Research Methodology</i> , 2020, 20, 253.	1.4	4
450	Metallic-based nanocarriers: methods employed in nanoparticle characterization and assessing the interaction with the blood-brain barrier. , 2020, , 255-282.		0
451	Interventions to help coral reefs under global change—A complex decision challenge. <i>PLoS ONE</i> , 2020, 15, e0236399.	1.1	70
452	Phase 0/microdosing approaches: time for mainstream application in drug development?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 801-818.	21.5	55
453	Drug Repurposing in Neurological Diseases: Opportunities and Challenges. , 0, , .		2
454	Research on Pharmaceutical Product Life Cycle Patterns for Sustainable Growth. <i>Sustainability</i> , 2020, 12, 8938.	1.6	2
455	Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 269-279.	1.8	29
456	Machine learning models for drug-target interactions: current knowledge and future directions. <i>Drug Discovery Today</i> , 2020, 25, 748-756.	3.2	105
457	Digitale Transformation von Dienstleistungen im Gesundheitswesen VII. , 2020, , .		1
458	Combination Therapies in Solid Tumour Oncology. , 2020, , 515-578.		0
459	At a glance: economic impact of industry-sponsored clinical trials of pharmaceutical products. <i>Journal of Medical Economics</i> , 2020, 23, 1193-1195.	1.0	1
460	Finding New Drugs for Infectious Diseases: Development Times and Success Rates. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 305-307.	2.3	1
461	Peptide drugs for photopharmacology: how much of a safety advantage can be gained by photocontrol?. <i>Future Drug Discovery</i> , 2020, 2, .	0.8	16
462	Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria. <i>Journal of Medical Economics</i> , 2020, 23, 566-574.	1.0	5

#	ARTICLE	IF	CITATIONS
463	Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA - Journal of the American Medical Association, 2020, 323, 844.	3.8	729
464	Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. Drug Safety, 2020, 43, 567-582.	1.4	9
465	Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy. Therapeutic Innovation and Regulatory Science, 2020, 54, 544-551.	0.8	1
466	Rushed Innovation: Evidence from Drug Licensing. Management Science, 2021, 67, 257-278.	2.4	13
467	Inducing Compliance with Postmarket Studies for Drugs Under FDA's Accelerated Approval Pathway. Manufacturing and Service Operations Management, 2021, 23, 170-190.	2.3	6
468	The Role of <i>p</i> -Values in Judging the Strength of Evidence and Realistic Replication Expectations. Statistics in Biopharmaceutical Research, 2021, 13, 6-18.	0.6	42
469	Exploratory Analysis of the Factors Associated With Success Rates of Confirmatory Randomized Controlled Trials in Cancer Drug Development. Clinical and Translational Science, 2021, 14, 260-267.	1.5	3
470	The U.S. medicine chest: Understanding the U.S. pharmaceutical supply chain and the role of the pharmacist. Journal of the American Pharmacists Association: JAPhA, 2021, 61, e87-e92.	0.7	9
471	Nanomedicines for Brain Drug Delivery. Neuromethods, 2021, , .	0.2	3
472	Killer Acquisitions. Journal of Political Economy, 2021, 129, 649-702.	3.3	221
473	Artificial Intelligence Effecting a Paradigm Shift in Drug Development. SLAS Technology, 2021, 26, 3-15.	1.0	12
474	Integrative genomics of aging. , 2021, , 151-171.		1
475	Accelerating proof of concept by smart early clinical trials. , 2021, , 257-261.		0
476	Protein Structure, Dynamics and Assembly: Implications for Drug Discovery. , 2021, , 91-122.		1
477	Dexmedetomidine and Ketamine – Comrades on an eternal journey!. Indian Journal of Anaesthesia, 2021, 65, 1.	0.3	18
478	Biomarkers. , 2022, , 693-724.		5
479	A Nickel(II)-Mediated Thiocarbonylation Strategy for Carbon Isotope Labeling of Aliphatic Carboxamides. Chemistry - A European Journal, 2021, 27, 7114-7123.	1.7	10
480	Developing Novel Anticancer Drugs for Targeted Populations: An Update. Current Pharmaceutical Design, 2021, 27, 250-262.	0.9	3

#	ARTICLE	IF	CITATIONS
482	3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination. <i>Scientific Reports</i> , 2021, 11, 4259.	1.6	20
483	Do pharmaceutical prices rise anticipating branded competition?. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1070-1081.	0.8	0
484	Computationally designed peptide macrocycle inhibitors of New Delhi metallo- β -lactamase 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	41
486	Heterocellular spheroids of the neurovascular blood-brain barrier as a platform for personalized nanoneuromedicine. <i>IScience</i> , 2021, 24, 102183.	1.9	33
487	Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery. <i>Frontiers in Chemistry</i> , 2021, 9, 607139.	1.8	4
488	Approval success rates of drug candidates based on target, action, modality, application, and their combinations. <i>Clinical and Translational Science</i> , 2021, 14, 1113-1122.	1.5	35
489	A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework. <i>Pharmaceutics</i> , 2021, 13, 488.	2.0	13
490	Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi. <i>Pharmaceutics</i> , 2021, 14, 488.	1.7	24
491	Three-Dimensional in vitro Models of Healthy and Tumor Brain Microvasculature for Drug and Toxicity Screening. <i>Frontiers in Toxicology</i> , 2021, 3, 656254.	1.6	12
492	Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development. <i>Pharmaceutics</i> , 2021, 14, 525.	1.7	10
493	Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development. <i>Drug Discovery Today</i> , 2021, 26, 1330-1336.	3.2	3
494	Mechanistic evaluation of a novel cyclohexenone derivative's functionality against nociception and inflammation: An in-vitro, in-vivo and in-silico approach. <i>European Journal of Pharmacology</i> , 2021, 902, 174091.	1.7	18
495	Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 672916.	1.3	16
496	The Establishment of a Fast and Safe Orthotopic Colon Cancer Model Using a Tissue Adhesive Technique. <i>Cancer Research and Treatment</i> , 2021, 53, 733-743.	1.3	1
497	Trends in kinase drug discovery: targets, indications and inhibitor design. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 839-861.	21.5	340
498	How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. <i>Pharmacoeconomics</i> , 2021, 39, 1243-1269.	1.7	94
499	Drug Screening, Oral Bioavailability and Regulatory Aspects: A Need for Human Organoids. <i>Pharmaceutics</i> , 2021, 13, 1280.	2.0	12
500	Building better biobetters: From fundamentals to industrial application. <i>Drug Discovery Today</i> , 2022, 27, 65-81.	3.2	11

#	ARTICLE	IF	CITATIONS
501	Engineering islets from stem cells for advanced therapies of diabetes. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 920-940.	21.5	61
502	Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis. <i>Computers in Biology and Medicine</i> , 2021, 136, 104677.	3.9	8
503	Molecular and evolutionary basis for survival, its failure, and virulence factors of the zoonotic nematode <i>Anisakis pegreffii</i> . <i>Genomics</i> , 2021, 113, 2891-2905.	1.3	11
505	Chemogenomic Approaches for Revealing Drug Target Interactions in Drug Discovery. <i>Current Genomics</i> , 2021, 22, 328-338.	0.7	2
506	The impact of product innovation announcements on firm value: evidence from the bio-pharmaceutical industry. <i>Industry and Innovation</i> , 0, , 1-28.	1.7	2
507	Eâ€FLOAT: Extractable Floating Liquid Gelâ€Based Organâ€onâ€aâ€Chip for Airway Tissue Modeling under Airflow. <i>Advanced Materials Technologies</i> , 2021, 6, 2100828.	3.0	9
508	Improving Translational Research Outcomes for Opioid Use Disorder Treatments. <i>Current Addiction Reports</i> , 2021, 8, 109-121.	1.6	9
509	The Role of Natural Products as Sources of Therapeutic Agents for Innovative Drug Discovery. , 2022, , 408-422.		42
510	Clinical translation status of nanoformulations. , 2021, , 303-338.		5
511	Late-stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997â€2016. <i>Clinical Therapeutics</i> , 2021, 43, 156-171.e15.	1.1	4
512	Genetics and Drug Discovery. , 2021, , 251-266.		1
513	Repurposing of a muscle relaxant drug thiocolchicoside as an anticancer agent. <i>MGM Journal of Medical Sciences</i> , 2021, 8, 33.	0.1	0
514	High-throughput organ-on-chip platform with integrated programmable fluid flow and real-time sensing for complex tissue models in drug development workflows. <i>Lab on A Chip</i> , 2021, 21, 1454-1474.	3.1	107
518	The In Silico Fischer Lock-and-Key Model: The Combined Use of Molecular Descriptors and Docking Poses for the Repurposing of Old Drugs. <i>Methods in Molecular Biology</i> , 2020, 2089, 29-39.	0.4	7
519	Pharmacometrics in Cardiovascular Safety. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 189-227.	0.2	3
520	Strategies and Methods for Drug Candidate Phase Optimization in Discovery Space. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015, , 209-240.	0.2	1
521	GeneCloud: Secure Cloud Computing for Biomedical Research. , 2014, , 3-14.		2
522	Introduction: Biomarkers in Translational and Personalized Medicine. <i>RSC Drug Discovery Series</i> , 2013, , 3-39.	0.2	1

#	ARTICLE	IF	CITATIONS
524	Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi. <i>Healthcare Policy</i> , 2019, 15, 70-80.	0.3	7
525	Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action. <i>PLoS Computational Biology</i> , 2015, 11, e1004202.	1.5	17
526	Risk in Vaccine Research and Development Quantified. <i>PLoS ONE</i> , 2013, 8, e57755.	1.1	191
527	Translational Science by Public Biotechnology Companies in the IPO "Class of 2000": The Impact of Technological Maturity. <i>PLoS ONE</i> , 2013, 8, e82195.	1.1	6
528	Timelines of translational science: From technology initiation to FDA approval. <i>PLoS ONE</i> , 2017, 12, e0177371.	1.1	43
529	Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2012, 29, 251-260.	0.9	42
530	p53 pulse modulation differentially regulates target gene promoters to regulate cell fate decisions. <i>Molecular Systems Biology</i> , 2019, 15, e8685.	3.2	29
531	Analysis of randomized clinical trials leading to new drug approvals in India and USA. <i>International Journal of Clinical Trials</i> , 2016, 3, 68.	0.0	2
532	Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. <i>Oncotarget</i> , 2017, 8, 50376-50392.	0.8	33
533	Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems. <i>Oncotarget</i> , 2015, 6, 9646-9656.	0.8	10
534	In Silico Chemogenomics Drug Repositioning Strategies for Neglected Tropical Diseases. <i>Current Medicinal Chemistry</i> , 2019, 26, 4355-4379.	1.2	24
535	Targeting Functional Biomarkers in Schizophrenia with Neuroimaging. <i>Current Pharmaceutical Design</i> , 2016, 22, 2117-2123.	0.9	10
536	ChemVassa: A New Method for Identifying Small Molecule Hits in Drug Discovery. <i>Open Medicinal Chemistry Journal</i> , 2012, 6, 29-34.	0.9	5
537	Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data. <i>JMIR Medical Informatics</i> , 2016, 4, e30.	1.3	16
538	Using Inside-Out Open Innovation to Recover Abandoned Pharmaceutical Compounds. <i>Journal of Innovation Management</i> , 2015, 3, 21-32.	0.9	21
539	Translational science: Key features, issues and future perspectives. <i>Translational and Regulatory Sciences</i> , 2019, 1, 1-3.	0.2	1
540	Drug Discovery. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2019, , 1-46.	0.3	1
541	Point-of-care and utility in clinical trials: making quicker decisions to transform patient care and drug development. <i>Bioanalysis</i> , 2020, 12, 1039-1041.	0.6	2

#	ARTICLE	IF	CITATIONS
542	A Discussion of the Role of Complex Evolved Systems in the Development of Invasive Cardiovascular Interventions as Illustrated by the Blalock- Taussig Shunt and Intra-Arterial Stents. <i>Biological Systems, Open Access</i> , 2014, 03, .	0.1	3
543	Business Model Innovation Opportunities for the Biopharmaceutical Industry: A Systematic Review. <i>Journal of Commercial Biotechnology</i> , 2016, 22, .	0.2	13
544	Variation of Cost among Anti-cancer Drugs Available in Indian Market. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, FC17-FC20.	0.8	16
545	Behavioral Treatment Development. , 2021, , 27-68.		5
546	Artificial intelligence in the prediction of proteinâ€“ligand interactions: recent advances and future directions. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	78
547	Blood Immune Cell Composition Associated with Obesity and Drug Repositioning Revealed by Epigenetic and Transcriptomic Conjoint Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 714643.	1.6	1
548	Statistical Issues of Worldwide Simultaneous Clinical Drug Development ^ ^mdash;Introduction^ ^mdash;. <i>Japanese Journal of Biometrics</i> , 2011, 32, S105-S119.	0.0	0
549	Critical Human Hepatocyte-Based In Vitro Assays for the Evaluation of Adverse Drug Effects. , 0, , .		0
551	Dynamic Dual Capacity Sourcing for New Ethical Drugs. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
555	Nanotechnology-Based Therapeutic Product Development and Commercialisation. , 2013, , 567-590.		0
556	Disease Modeling and Drug Discovery Using Human Pluripotent Stem Cells. <i>Pancreatic Islet Biology</i> , 2013, , 317-340.	0.1	0
557	Pharmaceutical Economics and Market Access for Pediatric Medications. , 0, , 37-56.		2
558	Medical Imaging in Drug Development. , 2014, , 99-133.		1
559	Privacy-Preserving Cloud Computing for Biomedical Research. , 2014, , 259-282.		0
560	Development of New Therapeutical Agents for Treatment of Insomnia and Other Sleeps Disorders. <i>Milestones in Drug Therapy</i> , 2015, , 85-107.	0.1	0
561	Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?. <i>Perspectives on Sustainable Growth</i> , 2015, , 39-68.	0.3	1
566	Big Pharma Entanglement with Biomedical Science. , 2016, , 213-243.		0
568	The Unaccounted Insurance Value of Medical Innovation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
569	Repurposing Drugs in the Genomics Era: Bioinformatics Approaches. MOJ Proteomics & Bioinformatics, 2016, 3, .	0.1	0
570	Clinical Testing of a New Drug. Springer Series in Pharmaceutical Statistics, 2017, , 1-18.	0.0	0
571	Generation and Application of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Cardiac and Vascular Biology, 2017, , 67-106.	0.2	0
572	A Review on: Phase 0â€™ Clinical Trials or Exploratory Investigational New Drug. Turkish Journal of Pharmaceutical Sciences, 2017, 14, 84-89.	0.6	4
575	Inducing Compliance with Post-Market Studies for Drugs Under FDAâ€™s Accelerated Approval Pathway. SSRN Electronic Journal, 0, , .	0.4	0
576	Rushed Innovation: Reactive Licensing in the Pharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	0
577	Safe Drugs Versus Innovative Drugs (Can We Have Both?). Advanced Pharmaceutical Bulletin, 2020, 10, 334-337.	0.6	2
578	Integration of Phytochemicals and Phytotherapy into Cancer Precision Medicine. Human Perspectives in Health Sciences and Technology, 2020, , 355-392.	0.2	1
581	Limitations and Flaws of Preclinical Pulmonary Hypertension Studies. Advances in Pulmonary Hypertension, 2020, 19, 47-54.	0.1	0
582	Die Bedeutung von Big Data f¼r klinische Entwicklungen und den Marktzugang. , 2020, , 209-240.		0
583	Downstream Processes. New Paradigms of Living Systems, 2020, , 105-136.	0.4	0
584	Introduction on translational autoimmunity: From bench to bedside. , 2022, , 1-12.		0
585	Portfolio and project planning and management in the drug discovery, evaluation, development, and regulatory review process. , 2022, , 537-562.		0
586	Design of clinical development programs. , 2022, , 653-679.		0
587	Nose-to-Brain Drug Delivery Enabled by Nanocarriers. Neuromethods, 2021, , 209-233.	0.2	0
588	Foldit Drug Design Game Usability Study: Comparison of Citizen and Expert Scientists. , 2020, , .		0
591	Clinical Testing of a New Drug. Springer Series in Pharmaceutical Statistics, 2021, , 1-21.	0.0	0
592	The roles of computer-aided drug synthesis in drug development. Green Synthesis and Catalysis, 2022, 3, 11-24.	3.7	8

#	ARTICLE	IF	CITATIONS
593	Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?. Postgraduate Medicine, 2022, 134, 187-199.	0.9	8
594	The Impact of R&D Cooperations on Drug Variety Offered on the Market. Evidence from the Pharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	1
595	To "or not to ", that is the question: A narrative review on P value. Cancer Research Statistics and Treatment, 2021, 4, 756.	0.1	6
596	Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors. Therapeutic Innovation and Regulatory Science, 2022, 56, 313-322.	0.8	15
597	Regulatory review of new product innovation: Conceptual clarity and future research directions. Technological Forecasting and Social Change, 2022, 175, 121419.	6.2	5
598	Report on History of FDA and NMPA and Traditional and Future Methods of Treating Cancer. , 2021, , .		0
599	Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform" A Cardiac Perspective. Cells, 2021, 10, 3483.	1.8	7
600	Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases. Future Medicinal Chemistry, 2022, 14, 271-288.	1.1	8
601	Laponite"Based Nanomaterials for Drug Delivery. Advanced Healthcare Materials, 2022, 11, e2102054.	3.9	48
602	Longitudinal study of the impact of three major regulations on the Korean pharmaceutical industry in the last 30 years. Health Research Policy and Systems, 2022, 20, 4.	1.1	1
603	Nanoparticles in Clinical Translation for Cancer Therapy. International Journal of Molecular Sciences, 2022, 23, 1685.	1.8	91
605	Views on artificial intelligence (AI) assisted clinical trials. Bioinformation, 2021, 17, 616-622.	0.2	0
606	Regulatory landscape in the approval of cancer vaccine. , 2022, , 325-348.		0
607	Rapid Response in an Uncertain Environment: Study of COVID-19 Scientific Research Under the Parallel Model. Risk Management and Healthcare Policy, 2022, Volume 15, 339-349.	1.2	1
608	Brain microvascular endothelial cells derived from human induced pluripotent stem cells as in vitro model for assessing blood-brain barrier transferrin receptor-mediated transcytosis. Materials Today Bio, 2022, 14, 100232.	2.6	13
609	Real-time monitoring of immediate drug response and adaptation upon repeated treatment in a microfluidic chip system. Archives of Toxicology, 2022, 96, 1483-1487.	1.9	2
610	Identification of Chemical" Disease Associations Through Integration of Molecular Fingerprint, Gene Ontology and Pathway Information. Interdisciplinary Sciences, Computational Life Sciences, 2022, , 1.	2.2	0
611	Emerging Subspecialties in Neurology: A Career as a Clinical Trialist in Neurology. Neurology, 2022, 98, 940-944.	1.5	2

#	ARTICLE	IF	CITATIONS
612	Triggered azobenzene-based prodrugs and drug delivery systems. <i>Journal of Controlled Release</i> , 2022, 345, 475-493.	4.8	51
613	Computational Methods for Structure-Based Drug Design Through System Biology. <i>Methods in Molecular Biology</i> , 2022, 2385, 161-174.	0.4	1
614	The importance of drug target selection capability for new drug innovation: definition, fostering process, and interaction with organizational management. <i>Prometheus</i> , 2020, 36, .	0.2	0
615	Computationally repurposing drugs for breast cancer subtypes using a network-based approach. <i>BMC Bioinformatics</i> , 2022, 23, 143.	1.2	8
616	Combinations of Drug Candidate Properties Affecting Development Success and Discontinuation for 5 Diseases: Lymphoma, Non-Small Cell Lung Cancer, Arthritis, Depression, and Alzheimer Disease. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1247-1256.	1.0	0
617	Channeling™ therapeutic discovery for epileptic encephalopathy through iPSC technologies. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 392-405.	4.0	10
620	Estimates of Probabilities of Successful Development of Pain Medications: An Analysis of Pharmaceutical Clinical Development Programs from 2000 to 2020. <i>Anesthesiology</i> , 2022, 137, 243-251.	1.3	13
621	Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects. <i>Medicine in Drug Discovery</i> , 2022, 15, 100134.	2.3	39
622	Application of Mathematical Modeling and Computational Tools in the Modern Drug Design and Development Process. <i>Molecules</i> , 2022, 27, 4169.	1.7	19
623	Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
624	Repurposing of parenterally administered active substances used to treat pain both systemically and locally. <i>Drug Discovery Today</i> , 2022, 27, 103321.	3.2	3
625	Tools shaping drug discovery and development. <i>Biophysics Reviews</i> , 2022, 3, .	1.0	3
626	Does consumer demand pull scientifically novel drug innovation?. <i>RAND Journal of Economics</i> , 2022, 53, 590-638.	1.3	7
627	Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG). <i>International Journal of Molecular Sciences</i> , 2022, 23, 8725.	1.8	5
628	Organ-on-a-chip: A new tool for in vitro research. <i>Biosensors and Bioelectronics</i> , 2022, 216, 114626.	5.3	16
629	Emergent treatments for β^2 -thalassemia and orphan drug legislations. <i>Drug Discovery Today</i> , 2022, 27, 103342.	3.2	2
630	Screening strategies for drug discovery-focus on ocular hypertension. , 2022, , 91-117.		0
631	Investigational new drug-enabling studies for ocular and other therapeutics. , 2022, , 131-146.		0

#	ARTICLE	IF	CITATIONS
632	The potential of a data centred approach & knowledge graph data representation in chemical safety and drug design. Computational and Structural Biotechnology Journal, 2022, 20, 4837-4849.	1.9	3
633	Target Discovery for Drug Development Using Mendelian Randomization. Methods in Molecular Biology, 2022, , 1-20.	0.4	5
635	S-04-03 BrainSpheres: applications and future. Toxicology Letters, 2022, 368, S18.	0.4	0
636	Examining African contributions to global health: Reflections on knowledge circulation and innovation. Global Public Health, 2023, 18, .	1.0	1
637	Naltrexone Transport by a Proton-Coupled Organic Cation Antiporter in hCMEC/D3 Cells, an &in Vitro& Human Bloodâ€ Brain Barrier Model. Biological and Pharmaceutical Bulletin, 2022, 45, 1585-1589.	0.6	0
638	Artificial Intelligence Approaches in Drug Discovery: Towards the Laboratory of the Future. Current Topics in Medicinal Chemistry, 2022, 22, 2176-2189.	1.0	2
639	Evaluating molecular fingerprint-based models of drug side effects against a statistical control. Drug Discovery Today, 2022, 27, 103364.	3.2	3
640	Financing Biomedical Innovation. Annual Review of Financial Economics, 2022, 14, 231-270.	2.5	14
641	Possibility Extent and Possible Alternatives Preorder Type-2 Fuzzy Analytical Hierarchy Process (PE&PAP-AHP) to improve pharmaceutical R&D productivity. Applied Soft Computing Journal, 2022, 131, 109770.	4.1	0
642	Monoclonal antibodies: Trends in therapeutic success and commercial focus. Drug Discovery Today, 2023, 28, 103415.	3.2	6
643	Therapeutic approaches to combat the global antibiotic resistance challenge. Future Microbiology, 2022, 17, 1515-1529.	1.0	5
644	Safety Pharmacology Evaluation of Biopharmaceuticals. , 2022, , 1-16.		0
645	Hibernation or Transformation? Challenges in Cardiovascular Drug Development. Frontiers in Cardiovascular Drug Discovery, 2022, , 102-140.	0.0	0
646	Engineered Human Muscle Tissue from Multilayered Aligned Myofiber Sheets for Studies of Muscle Physiology and Predicting Drug Response. Small Methods, 2023, 7, .	4.6	4
647	Rival Signals and Project Selection: Insights from the Drug Development Process. Management Science, 0, , .	2.4	3
648	Estimating drug-induced liver injury risk by in vitro molecular initiation response and pharmacokinetic parameters for during early drug development. Toxicology Research, 0, , .	0.9	0
649	Calculating the Binding Entropy of Host-Guest Systems with Physics-Guided Neural Networks. , 2022, , .		0
650	Investigation of the Relationship between Clinical Trial Design of Randomized Controlled Trials and Scientific Influence of the Trial Outcome in Non-small Cell Lung Cancer. Iryo Yakugaku (Japanese) Tj ETQq1 1 0.7846.14 rgBT (Overlock		

#	ARTICLE	IF	CITATIONS
651	The Returns to Medical Inventions. <i>Journal of Law and Economics</i> , 2022, 65, S389-S417.	0.6	0
652	Pharma's Bio-AI revolution. <i>Drug Discovery Today</i> , 2023, 28, 103515.	3.2	2
654	Strategies to Combat Multidrug Resistance by Non-traditional Therapeutic Approaches. , 2023, , 57-78.		0
655	Approved Protein Therapeutics and Their Biochemical Targets. , 2023, , 199-232.		0
656	Financial intermediation and the funding of biomedical innovation: A review. <i>Journal of Financial Intermediation</i> , 2023, 54, 101028.	1.4	5
657	Recent Advances on Cell Culture Platforms for In Vitro Drug Screening and Cell Therapies: From Conventional to Microfluidic Strategies. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	12
658	Drug discovery: Chaos can be your friend or your enemy. , 2023, , 417-511.		2
659	Backgrounder"Part 1. , 2023, , 3-26.		0
660	The role of healthcare institutions in translational surgical research. , 2023, , 641-646.		0
661	Investigational new drugs. , 2023, , 509-512.		0
662	Gex2SGen: Designing Drug-like Molecules from Desired Gene Expression Signatures. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 1882-1893.	2.5	5
663	Anthelmintic Drugs as Emerging Immune Modulators in Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6446.	1.8	3
665	Translational Science. , 2023, , 514-532.		0
667	Translatable Models of Brain and Cognitive Reserve. <i>Contemporary Clinical Neuroscience</i> , 2023, , 93-119.	0.3	0
685	Discovering Novel Pharmaceutical Molecules with Generative Adversarial Networks. , 2023, , .		0
688	In Vitro and In Vivo Metabolism Studies. , 2023, , 1-21.		0
691	Computational chemistry of natural product analogues. , 2024, , 395-437.		0
693	Assessing Policy Impact on Chemical Inventions: The Case of the Stockholm Convention. <i>SpringerBriefs in Economics</i> , 2024, , 19-37.	0.1	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------